(S (PP (IN With) (NP (NP (DT the) (NN advent)) (PP (IN of) (NP (JJ deep) (JJ generative) (NNS models))) (PP (IN in) (NP (JJ computational) (NN chemistry))))) (, ,) (NP (ADVP (IN in) (JJ silico)) (JJ anticancer) (NN drug) (NN design)) (VP (VBZ has) (VP (VBN undergone) (NP (DT an) (JJ unprecedented) (NN transformation)))) (. .))
(S (SBAR (IN While) (S (NP (JJ state-of-the-art) (JJ deep) (NN learning) (NNS approaches)) (VP (VBP have) (VP (VBN shown) (NP (JJ potential)) (PP (IN in) (S (VP (VBG generating) (NP (NP (NNS compounds)) (PP (IN with) (NP (JJ desired) (NN chemical) (NNS properties))))))))))) (, ,) (NP (PRP they)) (VP (VBP disregard) (NP (NP (DT the) (NX (NX (JJ genetic) (NN profile)) (CC and) (NX (NNS properties)))) (PP (IN of) (NP (DT the) (NN target) (NN disease))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP introduce) (NP (NP (DT the) (JJ first) (JJ generative) (NN model)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG tailoring) (NP (NN anticancer) (NNS compounds)) (PP (IN for) (NP (DT a) (JJ specific) (NN biomolecular) (NN profile))))))))) (. .))
(S (S (VP (VBG Using) (NP (DT a) (NNP RL) (NN framework)))) (, ,) (NP (NP (DT the) (JJ transcriptomic) (NNS profiles)) (PP (IN of) (NP (NN cancer) (NNS cells)))) (VP (VBP are) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN context)) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN candidate) (NNS molecules))))))))) (. .))
(S (NP (PRP$ Our) (NN molecule) (NN generator)) (VP (NNS combines) (NP (NP (NP (CD two) (ADJP (RB separately) (VBD pretrained)) (JJ variational) (NNS autoencoders)) (PRN (-LRB- -LRB-) (NP (NNP VAEs)) (-RRB- -RRB-))) (: -) (S (NP (DT the) (JJ first) (NNP VAE)) (VP (NNS encodes) (NP (JJ transcriptomic) (NNS profiles)) (PP (IN into) (NP (DT a) (JJ smooth) (, ,) (JJ latent) (NN space))) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ is) (VP (VBN used) (S (VP (TO to) (VP (VB condition) (S (NP (DT a) (JJ second) (NNP VAE)) (VP (TO to) (VP (VB generate) (NP (JJ novel) (JJ molecular) (NNS structures)) (PP (IN on) (NP (DT the) (VBN given) (JJ transcriptomic) (NN profile))))))))))))))))) (. .))
(S (NP (DT The) (JJ generative) (NN process)) (VP (VBZ is) (VP (VBN optimized) (PP (IN through) (NP (NP (NNP PaccMann)) (, ,) (NP (DT a) (ADJP (RB previously) (VBN developed)) (NN drug) (NN sensitivity) (NN prediction) (NN model)))) (S (VP (TO to) (VP (VB obtain) (NP (JJ effective) (NN anticancer) (NNS compounds)) (PP (IN for) (NP (NP (DT the) (VBN given) (NN context)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (JJ transcriptomic) (NN profile)) (-RRB- -RRB-))))))))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (WHADVP (WRB how)) (S (NP (DT the) (NN molecule) (NN generation)) (VP (MD can) (VP (VB be) (VP (VBN biased) (PP (NNS towards) (NP (NP (NNS compounds)) (PP (IN with) (NP (NP (JJ high) (VBN predicted) (JJ inhibitory) (NN effect)) (PP (IN against) (NP (NP (JJ individual) (NN cell) (NNS lines)) (CC or) (NP (JJ specific) (NN cancer) (NNS sites)))))))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP verify) (NP (PRP$ our) (NN approach)) (PP (IN by) (S (VP (VBG investigating) (NP (NP (NN candidate) (NNS drugs)) (VP (VBD generated) (PP (IN against) (NP (JJ specific) (NN cancer) (NNS types))))))))) (CC and) (VP (VB find) (NP (NP (DT the) (JJS highest) (JJ structural) (NN similarity)) (PP (TO to) (NP (NP (VBG existing) (NNS compounds)) (PP (IN with) (NP (NP (JJ known) (NN efficacy)) (PP (IN against) (NP (DT these) (NN cancer) (NNS types)))))))))) (. .))
(S (NP (PRP We)) (VP (VBP envision) (S (NP (PRP$ our) (NN approach)) (VP (TO to) (VP (VB transform) (NP (ADJP (IN in) (JJ silico)) (JJ anticancer) (NN drug) (NN design)) (PP (IN by) (S (VP (VBG leveraging) (NP (NP (DT the) (JJ biomolecular) (NNS characteristics)) (PP (IN of) (NP (DT the) (NN disease))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB increase) (NP (NP (NN success) (NNS rates)) (PP (IN in) (NP (JJ lead) (NN compound) (NN discovery)))))))))))) (. .))
